发明名称 |
USES OF ANTI-CD40 ANTIBODIES |
摘要 |
Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan®), are also provided.;The methods of the present invention find use in treatment of cancers and pre-malignant conditions that are associated with CD40-expressing cells. These methods are particularly advantageous with respect to cancers and pre-malignant conditions that are associated with cells expressing both CD40 and CD20, as the methods enable the treatment of patients having a cancer or pre-malignant condition that is refractory to therapy with other oncotherapeutic agents such as anti-CD20 antibodies. |
申请公布号 |
US2015086991(A1) |
申请公布日期 |
2015.03.26 |
申请号 |
US201414553254 |
申请日期 |
2014.11.25 |
申请人 |
Novartis AG ;XOMA Technology Ltd. |
发明人 |
Aukerman Sharon Lea;Luqman Mohammad |
分类号 |
C12Q1/68 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method for identifying a human patient with a cancer or pre-malignant condition treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), comprising:
a) identifying a human patient with a cancer or pre-malignant condition that is associated with CD40-expressing cells; and b) determining said human patient's FcγRIIIa-158 genotype (V/V, V/F or F/F);wherein said cancer or pre-malignant condition is treatable with an anti-CD40 antibody if said human patient is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). |
地址 |
Basel CH |